NDA 021908 · Sucampo Pharma LLC
Amitiza
Lubiprostone · Oral · Chloride Channel Activator
NovelLast checked: Nov 19, 2026Latest source record: Nov 30, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2006
Jan 31, 2006
Approved uses
4
Original approval plus efficacy supplements
Registered trials
51
24 Phase 3, 2 recruiting
FAERS reports
9,556
6,379 serious, 972 with death reported
AI brief across all sources
Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 28, 2026.
Lubiprostone is a chloride channel activator indicated for the treatment of: chronic idiopathic constipation (CIC) in adults. ( 1.1 ) opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. ( 1.2 ) Limitations of Use: Effectiveness of lubiprostone in the treatment of OIC in patients taking diphenylheptane opioids (e.g., methadone) has not been established. ( 1.2 , 7.1 ) irritable bowel syndrome with constipation (IBS-C) in women ≥ 18 years old. ( 1.3 ) 1.1 Chronic Idiopathic Constipation in Adults Lubiprostone is indicated for the treatment of chronic idiopathic constipation (CIC) in adults. 1.2 Opioid-Induced Constipation in Adult Patients with Chronic Non-Cancer Pain Lubiprostone is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. Limitations of Use: Effectiveness of Lubiprostone in the treatment of opioid-induced constipation in patients taking diphenylheptane opioids (e.g., methadone) has not been established. [see Clinical Studies (14.2) ] 1.3 Irritable Bowel Syndrome with Constipation Lubiprostone is indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in women at least 18 years old.
Mechanism: Lubiprostone is a locally acting chloride channel activator that enhances a chloride-rich intestinal fluid secretion without altering sodium and potassium concentrations in the serum. Lubiprostone acts by specifically activating ClC-2, which is a normal constituent of the apical membrane of the human intestine, in a protein kinase A–independent fashion. By increasing intestinal fluid secretion, lubiprostone increases motility in the intestine, thereby facilitating the passage of stool and alleviating symptoms associated with chronic idiopathic constipation. Patch clamp cell studies in human...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 26, 2018 Supplement 16 · Efficacy · priority review LabelLetterPediatric Medical Review
- Apr 19, 2013 Supplement 11 · Efficacy · priority review ReviewLetterLabel
- Apr 29, 2008 Supplement 5 · Efficacy ReviewLetterLabel
- Jan 31, 2006 Original approval · Type 1 - New Molecular Entity NovelReviewLetterLabel
2 products under this application
- AMITIZA · LUBIPROSTONE 24MCG · CAPSULE, ORAL · Prescription · TE AB
- AMITIZA · LUBIPROSTONE 8MCG · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Lubiprostone" as an intervention, any sponsor and status, largest first.
- Evaluation of Clinical Equivalence Between Two Lubiprostone Products in the Treatment of Chronic Idiopathic ConstipationPivotal-lookingCompleted
Dr. Reddy's Laboratories Limited, IndiaIndustry
NCT01674530 · 909 participants · Start Oct 2012 · Primary completion Jan 2014
Drug: Lubiprostone; Lubiprostone and 1 more · For: Chronic Idiopathic Constipation
Sites: Birmingham, Alabama; Dothan, Alabama; Huntsville, Alabama · 93 sites in all
- Evaluation of Clinical Equivalence Between Two Lubiprostone ProductsPivotal-lookingCompleted
Anchen Pharmaceuticals, IncIndustry
NCT01372423 · 808 participants · Start May 2011 · Primary completion Jun 2012
Drug: Lubiprostone; Placebo · For: Chronic Idiopathic Constipation
Sites: Dothan, Alabama; Huntsville, Alabama; Mobile, Alabama · 79 sites in all
- Lubiprostone in Children With Functional ConstipationPivotal-lookingCompleted
Sucampo Pharma Americas, LLCIndustry
NCT02042183 · 606 participants · Start Dec 13, 2013 · Primary completion Jul 27, 2016
Drug: Lubiprostone; Placebo · For: Constipation - Functional
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 117 sites in all
- Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With ConstipationPivotal-lookingCompleted
Sucampo Pharma Americas, LLCIndustry
NCT00380250 · 590 participants · Start May 2005
Drug: Lubiprostone; Placebo · For: Irritable Bowel Syndrome With Constipation
- Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With ConstipationPivotal-lookingCompleted
Sucampo Pharma Americas, LLCIndustry
NCT00399542 · 581 participants · Start May 2005 · Primary completion Jul 2006
Drug: Lubiprostone; Placebo · For: Irritable Bowel Syndrome; Constipation
- Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to PlaceboPivotal-lookingCompleted
Sucampo Pharma Americas, LLCIndustry
NCT03097861 · 552 participants · Start Mar 13, 2017 · Primary completion Aug 17, 2017
Drug: Lubiprostone; Placebo · For: Chronic Idiopathic Constipation
Sites: Birmingham, Alabama; Foley, Alabama; Little Rock, Arkansas · 67 sites in all
- A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated AdultsPivotal-lookingCompleted
Braintree LaboratoriesIndustry
NCT02481947 · 459 participants · Start May 2015 · Primary completion Nov 2015
Drug: BLI400 Laxative; Lubiprostone · For: Chronic Idiopathic Constipation
Sites: Mobile, Alabama; Tucson, Arizona; Anaheim, California · 50 sites in all
- Comparative Study of Lubiprostone and PEG Preparation Versus Conventional PEG Preparation for ColonoscopyPivotal-lookingCompleted
Asian Institute of Gastroenterology, IndiaAcademic, hospital or other
NCT01324284 · 442 participants · Start Mar 2011 · Primary completion Jun 2011
Drug: Lubiprostone · For: Colorectal Carcinoma
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea803
- dyspnoea641
- diarrhoea633
- constipation584
- drug ineffective568
- fatigue544
- pain500
- headache498
- dizziness457
- fall409
- vomiting409
- off label use350
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2006 | 18 |
| 2007 | 98 |
| 2008 | 163 |
| 2009 | 182 |
| 2010 | 215 |
| 2011 | 210 |
| 2012 | 298 |
| 2013 | 315 |
| 2014 | 404 |
| 2015 | 633 |
| 2016 | 905 |
| 2017 | 788 |
| 2018 | 910 |
| 2019 | 883 |
| 2020 | 736 |
| 2021 | 591 |
| 2022 | 435 |
| 2023 | 439 |
| 2024 | 442 |
| 2025 | 476 |
| 2026 | 415 |
Recalls
3 FDA enforcement reports for this application.
May 13, 2019 · Class II · Terminated
Labeling: Label mix-up. Amitiza 8 mcg capsules are being recalled because 24 mcg capsules were found in a 8 mcg trade 60 ct. bottle. Amitiza 24 mcg capsules are being recalled because a sealed 60 ct. bottle contained...
May 13, 2019 · Class II · Terminated
Labeling: Label mix-up. Amitiza 8 mcg capsules are being recalled because 24 mcg capsules were found in a 8 mcg trade 60 ct. bottle. Amitiza 24 mcg capsules are being recalled because a sealed 60 ct. bottle contained...
Nov 6, 2018 · Class III · Terminated
Failed Impurities/Degradation Specifications:Elevated levels of a known impurity in the 20-month stability sample testing.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Amitiza (Lubiprostone)
2024 spending
$2.9M
Beneficiaries
2,368
6,887 claims
Per beneficiary
$1,229
$5.65 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $279,322,814 |
| 2021 | $89,363,650 |
| 2022 | $23,146,170 |
| 2023 | $8,420,705 |
| 2024 | $2,909,987 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis.
Luthra P, Camilleri M, Burr NE, et al. · Lancet Gastroenterol Hepatol 2019 · Research Support, N.I.H., Extramural, Systematic Review
- Comparative profiles of lubiprostone, linaclotide, and elobixibat for chronic constipation: a systematic literature review with meta-analysis and number needed to treat/harm.
Rao SS, Manabe N, Karasawa Y, et al. · BMC Gastroenterol 2024 · Comparative Study, Meta-Analysis
- Constipation in adults.
Mueller-Lissner SA, Wald A · BMJ Clin Evid 2010 · Systematic Review
- Treatments for intractable constipation in childhood.
Gordon M, Grafton-Clarke C, Rajindrajith S, et al. · Cochrane Database Syst Rev 2024 · Systematic Review, Meta-Analysis
- Management of irritable bowel syndrome.
Ford AC · Minerva Gastroenterol Dietol 2009 · Systematic Review
- Efficacy and safety of pharmacological therapies for functional constipation in children: a systematic review and meta-analysis.
de Geus A, Gordon M, Sinopoulou V, et al. · Lancet Child Adolesc Health 2025 · Systematic Review, Meta-Analysis
Sponsor: Sucampo Pharma LLC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.